Literature DB >> 8329701

Basic fibroblast growth factor promotes the proliferation of human megakaryocyte progenitor cells.

E Bruno1, R J Cooper, E L Wilson, J L Gabrilove, R Hoffman.   

Abstract

Basic fibroblast growth factor (bFGF), a multifunctional growth factor produced by bone marrow stromal cells, is known to be a potent modulator of hematopoiesis. Because bFGF is present in both human megakaryocytes (MKs) and platelets, we have hypothesized that this growth factor might affect human megakaryocytopoiesis. To test this hypothesis, either low density bone marrow (BM) cells (LDBM), a human BM subpopulation (CD34+ DR+) enriched for the colony-forming unit megakaryocyte (CFU-MK) or a BM subpopulation (CD34+ DR-) enriched for the more primitive burst-forming unit megakaryocyte (BFU-MK) were assayed in the presence of this growth factor. The effect of bFGF on MK colony formation differed according to the cell population assayed. bFGF alone had on MK colony-stimulating activity (MK-CSA) when either CD34+ DR+ or CD34+ DR- BM cells were cloned, but exhibited MK-CSA equivalent to that of interleukin-3 (IL-3) when LDBM cells were used as the target cell population. The MK-CSA of bFGF was inhibited by the addition of neutralizing antisera to either IL-3 and/or granulocyte-macrophage colony-stimulating factor (GM-CSF) but not IL-6. The addition of excess amounts of either IL-3 or GM-CSF to cultures containing bFGF plus anti-IL-3 or anti-GM-CSF reversed the inhibition by the corresponding antisera. The addition of bFGF and IL-3 to assays containing CD34+ DR+ or CD34+ DR- cells increased the size of both CFU-MK- and BFU-MK-derived colonies, respectively, when compared with assays containing IL-3 alone. This increase in MK colony size mediated by bFGF was not affected by addition of either an anti-GM-CSF or anti-IL-6 neutralizing antisera. When LDBM cells were assayed, bFGF alone increased CFU-MK-derived colony size when compared with control values. However, this potentiation of MK colony size by bFGF could be reversed by the addition of either anti-IL-3 or anti-GM-CSF but not anti-IL-6 antisera. In addition, the effects of bFGF and IL-3 on the size of MK colonies cloned from LDBM were not additive. These results suggest that bFGF affects human megakaryocytopoiesis by directly promoting MK progenitor cell proliferation and stimulating BM accessory cells to release growth factor(s) with MK-CSA, such as IL-3 and GM-CSF. We conclude that bFGF, likely produced by cellular components of the BM microenvironment, plays an important role in the control of human megakaryocytopoiesis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8329701

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Cytokine production by a megakaryocytic cell line.

Authors:  B Sandrock; K M Hudson; D E Williams; M A Lieberman
Journal:  In Vitro Cell Dev Biol Anim       Date:  1996-04       Impact factor: 2.416

2.  bFGF and Activin A function to promote survival and proliferation of single iPS cells in conditioned half-exchange mTeSR1 medium.

Authors:  Xiaoling Guo; Ruiling Lian; Yonglong Guo; Qing Liu; Qingshan Ji; Jiansu Chen
Journal:  Hum Cell       Date:  2015-03-10       Impact factor: 4.174

3.  Novel TPO receptor agonist TA-316 contributes to platelet biogenesis from human iPS cells.

Authors:  Ayako Aihara; Tomo Koike; Natsuki Abe; Sou Nakamura; Akira Sawaguchi; Takanori Nakamura; Naoshi Sugimoto; Hiromitsu Nakauchi; Taito Nishino; Koji Eto
Journal:  Blood Adv       Date:  2017-02-28

4.  Differential radioprotection of three mouse strains by basic or acidic fibroblast growth factor.

Authors:  P Okunieff; T Wu; K Huang; I Ding
Journal:  Br J Cancer Suppl       Date:  1996-07

Review 5.  The pathogenesis of chronic myeloproliferative diseases.

Authors:  A Tefferi
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

6.  Elevated levels of plasma angiogenic factors are associated with human lymphatic filarial infections.

Authors:  Sasisekhar Bennuru; Grace Maldarelli; V Kumaraswami; Amy D Klion; Thomas B Nutman
Journal:  Am J Trop Med Hyg       Date:  2010-10       Impact factor: 2.345

Review 7.  Myelofibrosis: pathogenesis of myelofibrosis with myeloid metaplasia. French INSERM Research Network on Myelofibrosis with Myeloid Metaplasia.

Authors:  M C Le Bousse-Kerdilès; M C Martyré
Journal:  Springer Semin Immunopathol       Date:  1999

8.  Bone marrow expression and plasma concentration of basic fibroblast growth factor in patients with idiopathic thrombocytopenic purpura.

Authors:  Bora Son; Kyeong Seob Shin; Sook Young Bae; Soo-Young Yoon
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

9.  FGF2 posttranscriptionally down-regulates expression of SDF1 in bone marrow stromal cells through FGFR1 IIIc.

Authors:  Takayuki Nakayama; Noriko Mutsuga; Giovanna Tosato
Journal:  Blood       Date:  2006-10-31       Impact factor: 22.113

10.  Release of GPI-anchored membrane proteins by a cell-associated GPI-specific phospholipase D.

Authors:  C N Metz; G Brunner; N H Choi-Muira; H Nguyen; J Gabrilove; I W Caras; N Altszuler; D B Rifkin; E L Wilson; M A Davitz
Journal:  EMBO J       Date:  1994-04-01       Impact factor: 11.598

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.